Treatment	Agents	Likely impact on RAR/RXR	Mesodermal yields		
			Adipo	Total Myo	CM
1	NI		θ	θ	θ
2	atRA	RARa + RXRa	+ +	+ +	+ +
3	TTNPB	RARa > RXRa	+ + +	θ	θ
4	atRA + RXRatg	RARa (RXR availability↓)	+ +	+	+
5	LG268	RXRa > RARa	+ +	+ +	+ +
6	atRA + RARatg	RXRa (RAR availability↓)	+ +	+ +	+ + / +
7	atRA + ERKi	RARa + RXRa	+ +	+ + +	+ + +
8	atRA + RXRatg + ERKi	RARa (RXR availability↓)	+ +	+ +	+ +
9	atRA + RARatg + ERKi	RXRa (RAR availability↓)	+ +	+ +	+ + / +
10	atRA + p38i	RARa + RXRa	+ + +	+ + +	+ +
11	atRA + RXRatg + p38i	RARa (RXR availability↓)	+ +	θ	θ
12	atRA + RARatg + p38i	RXRa (RAR availability↓)	θ	θ	θ

Mesodermal yields of all treatments are compared with atRA treatment (Treatment 2). Increased yields have an additional + sign, whereas decreased yields loss a + sign, and the symbol 0 is for the absence or great rarity of cells of the indicated phenotype. Adipocyte (Adipo) yields are based on Oil-Red-O staining, SKM + CM (total Myo) yields on α-actinin signal, and CM yields on MLC2v-GFP signal. RARa or RXRa, RAR or RXR activity; ERKi or p38i, inhibitor of ERK or p38 signaling.